GRIFOLS S A/S (GRFS) Lowered to “Strong Sell” at BidaskClub
A number of other equities research analysts also recently issued reports on the company. Morgan Stanley lowered their price objective on GRIFOLS S A/S from $20.00 to $19.00 and set an underweight rating on the stock in a research report on Wednesday, January 2nd. Berenberg Bank downgraded GRIFOLS S A/S from a buy rating to a hold rating in a research report on Friday, February 8th. Finally, Zacks Investment Research downgraded GRIFOLS S A/S from a hold rating to a sell rating in a research report on Tuesday, December 25th. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $21.00.
Shares of GRFS stock opened at $18.66 on Tuesday. The company has a current ratio of 2.77, a quick ratio of 1.22 and a debt-to-equity ratio of 1.30. GRIFOLS S A/S has a 52-week low of $17.42 and a 52-week high of $24.97. The firm has a market capitalization of $12.83 billion, a P/E ratio of 15.95, a price-to-earnings-growth ratio of 1.39 and a beta of 1.07.
Several hedge funds have recently modified their holdings of the stock. Financial Gravity Wealth Inc. bought a new position in GRIFOLS S A/S in the first quarter valued at $352,000. Mercer Global Advisors Inc. ADV bought a new position in GRIFOLS S A/S in the first quarter valued at $266,000. Deutsche Bank AG increased its stake in GRIFOLS S A/S by 670.3% in the fourth quarter. Deutsche Bank AG now owns 12,427,277 shares of the biotechnology company’s stock valued at $228,164,000 after acquiring an additional 10,813,901 shares during the last quarter. Norges Bank bought a new position in GRIFOLS S A/S in the fourth quarter valued at $57,748,000. Finally, Millennium Management LLC increased its stake in GRIFOLS S A/S by 34.9% in the fourth quarter. Millennium Management LLC now owns 1,618,236 shares of the biotechnology company’s stock valued at $29,711,000 after acquiring an additional 418,675 shares during the last quarter. Institutional investors own 19.96% of the company’s stock.
About GRIFOLS S A/S
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.
See Also: Should you buy a closed-end mutual fund?
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.